Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
Rhea-AI Summary
Liquidia (Nasdaq: LQDA) will report first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
The webcast will stream and be archived for one year at the company investor events page.
Positive
- None.
Negative
- None.
News Market Reaction – LQDA
In the May 4 session, LQDA gained 0.89%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings date notice | Neutral | +2.6% | Announced full-year 2025 earnings release date and webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited tag-specific history; the prior earnings date announcement saw a modest positive move after scheduling an earnings call.
Recent news for LQDA has highlighted scheduling and delivery of financial updates. The prior earnings date release on Feb 26, 2026 announced timing for full-year 2025 results and an associated webcast, with shares moving about 2.63% over the next day. Today’s notice for first quarter 2026 results continues this pattern of advance communication around earnings events.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
media@liquidia.com
